Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin

Talha Badar, Mehdi Hamadani, Veronika Bachanova, Kami J. Maddocks, Elvira Umyarova, Julio C. Chavez, Narendranath Epperla, Saurabh Chhabra, Ana C. Xavier, Reem Karmali, Mohammed Salhab, Nishitha Reddy, Martha J. Glenn, Francisco J. Hernandez-Ilizaliturri, Christopher R. Flowers, Andrew M. Evens, Zheng Zhou, Frederick Lansigan, Stefan K. Barta, Jonathon B. CohenTimothy S. Fenske, Luciano J. Costa*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

We evaluated outcome of 235 primary treatment failure (PTF) diffuse large B-cell lymphoma (DLBCL) patients based on salvage chemotherapy regimen and putative cell-of-origin (COO). Patients were divided into two groups; group A (n = 38) received high-dose cytarabine containing regimen, either DHAP or ESHAP. Patients in group B (n = 197) received ifosfamide, carboplatin, and etoposide (ICE) +/− rituximab. No difference in overall response rates (CR + PR) was observed based on salvage chemotherapy regimen and COO. After adjustment for the presence of ultra high-risk features, overall survival of germinal center B-cell like (GCB) DLBCL patients in group A was not significantly different from survival in group B (HR 0.86, 95% CI 0.46–1.60, p =.64). Similarly, within non-GCB DLBCL cohort, survival in group A was comparable to group B (HR 0.53, 95% CI 0.20–1.44, p =.21). We did not find an outcome difference between two commonly used salvage chemotherapy regimens in patients with PTF DLBCL based on COO.

Original languageEnglish (US)
Pages (from-to)940-946
Number of pages7
JournalLeukemia and Lymphoma
Volume60
Issue number4
DOIs
StatePublished - Mar 21 2019

Keywords

  • Refractory diffuse large B-cell lymphoma
  • germinal center B-cell like DLBCL
  • putative cell-of-origin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin'. Together they form a unique fingerprint.

Cite this